secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-07-11T23:59:59+00:00
Accession:  0001104659-24-079262
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar Biosciences dismisses Baker Tilly, hires Deloitte; cites material weaknesses
--------------------------------------------------------------------------------

- Audit Committee dismissed Baker Tilly and is engaging Deloitte & Touche as independent auditor for FY2024, subject to standard procedures.
- Baker Tilly's prior reports contained a going-concern emphasis paragraph; no disagreements except disclosed material weaknesses.
- Material weaknesses identified: fair value methodologies for Level 3 instruments, stock-based compensation controls, and segregation of duties/user access.
- No prior consultations with Deloitte on accounting principles or disagreements during fiscal years 2022-2023 and interim 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924079262/0001104659-24-079262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924079262/tm2419333d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-079262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer